Hyperactivated tumor survival pathways cannot be suppressed without coupling targeted inhibitors with companion diagnostics.
Because specific genomic alterations like PTEN deficiency drive rapid drug resistance and aggressive disease, regulatory approvals for next-generation inhibitors require mandatory matching companion diagnostics.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
The approval of Truqap is strictly linked to a mandatory companion diagnostic that screens patients for the specific PTEN-deficiency pathway driving their cancer.
The accelerated approval of camizestrant relies on a coupled companion diagnostic to detect ESR1 resistance mutations before clinical progression occurs.
Truqap's FDA approval for PTEN-deficient prostate cancer is strictly coupled with a mandatory companion diagnostic to target the specific signaling pathway driving the disease.
Gedatolisib's commercial success relies heavily on expanding routine biomarker companion diagnostics to identify the PIK3CA wild-type patients who benefit.
The approval of capivasertib for PTEN-deficient prostate cancer was paired with a mandatory companion diagnostic to identify eligible patients.